Member Info for sadoldgit

One more thing autoimmune disease market 68billion dollars 2022, forecast to reach 123 billion dollars by 2032.

Confident that we will outperform Deucravacitinib in Psoriasis.

Regards

Myleofibrosis market size circa 2.3 billion a year relating to Momoletonib

Psoriasis currently 27.5 billion a year forecast to reach 57 billion a year by 2032

IBD currently 22 billion a year

Both Psoriasis and IBD are Indications applicable to SDC1801 .

Regards

Reality10.

Yes lad and you should practice what you preach.

No good starting with the word 'if'

What is this pudding you refer to.

Sareum are not involved in any discussions relating to licensing of 737. That is entirely in the hands of the CPF.

An RNS with news on 737 could land anytime out of the blue.

This would follow the CPF notifying Sareum.

Good morning reality10.

Maybe you could supply factual information to substantiate your claim.

As far as l know Sierra oncology never tried once to give 737 away.

737 did not fit in GSK plans as they had just spent 5 billion dollars on the Tesaro pipeline so would definitely would not want to dilute that.

I will also inform you that 737 was taken down from the shop window in early 2020 by SO.

With respect to ongoing developments with 737 any negotiations are between the CPF and interested parties. Nothing to do with Sareum.

As l stated before there will be no mild to moderate adverse effects at 5mg per day.

What you read and what you think you understand are two different things.

Preclinical is a good predictor of clinical.

No significant adverse effects were observed at 30 times treatment regime in SDC1801 in Preclinical .

End of!

How on earth would l expect mild moderate AE's on a 5mg per day dose?

Dosing regime by Sareum set at upper limit of 1000 mg per day

At one 200th of the upper limit of treatment dosing how is it feasible to expect mild to moderate adverse events?

Mild to moderate adverse events at these levels would spell game over.

I suggest you take a good look at the preclinical history.

There will have been no adverse events at these doses!

Regards

As a further not very well.known factor the approval of dose escalation has also endorsed the safety profile of our SDC1802.

As already mentioned by Tim and Co there objective is to on license or sell at late stage preclinical or early stage clinical

The chances of total buyout have now increased as acceptable compound safety is the most essential aspect to development and progress to drug commercialisation.

Let that sink in.

Regards

Not surprised as such due to initial over caution as indicated by the very low trial dose

I would make a very educated guess that thus was due as to no maximum tolerated dose ever being reached in preclinical

I see no concerns with toxicity of our SDC compounds.

Only toxicity here is generated by the 2 Roverfort fanatics

Clearly they can only see one side of the coin due to whatever their agenda is.

Regards

Tox studies would have already started from initial dosing.

All looking good.

Good RNS. Commencement of trial was not well known as decision had yet to be made by ERC.

Now that the dose escalation trial has been approved it puts us a step closer to it licence or partnership.

The use of biomarkers will provide data on Indications that our Tyk2 Jak1 compound will.prove very favourable in.

We have the benefit of dual inhibition of which the efficacy benefits are known by many here.

No significant problems with Jak2 eg EPO or even lesser problems associated with Jak3 due to our selectivity over should be encountered.

It now comes down to science. Not a case of if we are good but just how good.

Capsule formulation

Crystallisation structure of a compound

Very long life patent protection

Pharmaceutical Companies in Dire need of auto immune pipeline development.

I for one certainly would not rule out a deal of some nature to be announced soon.

Regards

They know rather a lot about each other and each others plans. Timing of posts and may well be the same person.

Reversed psychology here with a couple of comment made on chatboard about each other as if they are individuals

Regards

Good morning Rebster408.

Should the price drop here we still hold shares and our investment. We have the option to add.

Should the price rise even on a blip then a couple of individuals will lose all their current investment.

Desperation l feel creeping in here from a certain individual.

It wants everyone to sell so the price plummets so it can make its money. Under the guise of it can make its money and gives us the opportunity to buy in cheaper.

I do recall one of its posts a few weeks ago claiming its work was done here. If so then why does it keeps pumping out its same old Dire consequences of the death spiral?

Regards

Bobbler it is evident by the number of posts by these couple of clowns that they are getting desperate.

It is easy to see the levels they will.sink to ie disruptive on this chat board indicating a sense of unease they have.

They know nothing about Sar which is abundantly evident. Indeed they are truly ignorant with a helping of degree of now childish behaviour.

One of the imbeciles have even lowered themselves to a poor attempt at sarcasm in a vain attempt to disrupt.

Poor little mites!

Regards to the truly invested

The only fact that stands out to me is the two recent additions to this chat board projecting a death spiral since the finance agreement with Riverfort has corresponded with a drop in the share price.

Are the sells due to Riverfort selling or fear installed by the 2 newbies? How many sells are due to Scaremongering?

If they are so sure of themselves then there really is no need to post here.

What us the intent of their posting if it is not to spread fear and uncertainty into long term investors?

They claim to know inside information?

They do not post here for anyones benefit apart from their own however they appear to dress it up.

Already been admitted by one that by selling shares by investors will.lower the SP that will benefit that individual.

Relentless posting of negative opinions since both came aboard. I see nothing constructive in that.

Note the times that they post. Last thing at night and first thing in the morning.

There are reasons they do this as they are well aware.

As one poster posted:-

'Those that have taken my advice and cosen to sell'

I will leave it at that.

Regards

I very much doubt they would increase the dosing regime as that has already been established.

Following on from the dosing regime it would however give excellent scope for treatment doses not only in psoriasis but also many Indications.

One thing we will prove advantageous over Deucravacitinib is Chrohns disease and Ulcerative colitus.

Regards

Sdc1801 should progress well right through to 300 mg per day

CCT245 737 was projected to be around 1000 mg maximum dose on safety.

Maximum tolerated dose was indeed established at 1000mg perday in monotherapy clinical trial.

Doses had been administered up to 1400 mg and at these levels downsides of side effects increased from 1200mg per day upwards.

Sdc1801 had no established MTD. It is not that the did not bother but had diffuculty, according to TM creating the compound in sufficient quantities to establish this MTD. At 30 times treatment dose no significant side effects were observed. We may have to go as high as 100 times he says but have no idea if this was ever carried out.

So the truly invested should have no due concerns as to the safety of the compound.

On good dose escalation news and dependant on just how good these results will be should have a corresponding significant increase in company value.

Tim and Co will have a better idea than us here as to that value.

Also take into account that on good dose escalation results SDC 1801 nigh guaranteed superiority over Deucra due to the advantage of dual kinase inhibition.

A company at this point will want to buy in whether on licence or takeover. Companies will want to maximise on commercialisation ie to be put to use in the clinic for as many treatments as possible.

A billion is not out of the question here. As time goes on and dose escalating results become known the likelihood of such an offer occurring increases. Indeed offers may be considerably lower or likewise considerably higher on full data results.

Tyk2 is a hot area but will be not as hot as a dual inhibitor with a similar safety profile.

All very logical if we understand what we have, an idea of the competition and what the commercialization companies want.

Good post ajithoth.

It is important to remember that the P53 checkpoint in a cell cycle is applicable to over 50% of cancer tumours alone. This referring to mutation of and development of a cancerous cell.

However by just using a chk inhibitor on its own will stem the production of mutant cells (hence stability and limited growth in treated cancers which can be seen in 737 clinical trial results) it has limited effect effect in tumour size reduction.

Therefore we are looking at the effectiveness of Chk1 in control of new cell growth.

To be effective chk1 inhibitors need to be used in conjunction with other cancer destroying or DNA damaging agents.

With regards to the importance of Chk1i and the P53 checkpoint nothing has changed.

Regards

Good evening Ahfam.

I think this the one you were referring too.

You need to read from about half way through.

https://www.sciencedirect.com/science/article/pii/S1556086419306926

737 LDG and PD-L1 ( ICB)

Regards

Https://ecancer.org/en/video/7768-efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model